Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Rhea-AI Summary
Cocrystal Pharma (NASDAQ: COCP) has reported positive Phase 1 results for CDI-988, its oral protease inhibitor designed as a pan-viral treatment for norovirus and coronavirus infections. The multiple-ascending dose (MAD) study demonstrated favorable safety and tolerability at dosing up to 800 mg daily for 10 consecutive days.
The company plans to conduct an additional cohort study with a higher dose of 1,200 mg for five consecutive days to further evaluate safety, tolerability, and pharmacokinetics. CDI-988, developed using Cocrystal's proprietary structure-based drug discovery platform, has shown pan-viral activity against multiple norovirus strains, particularly the GII.4 viruses.
With nearly 900 cruise ship passengers affected by gastrointestinal disease in December alone and no currently approved antivirals or vaccines for norovirus, Cocrystal aims to initiate a human challenge study in norovirus-infected subjects later in 2025.
Positive
- Successful Phase 1 safety and tolerability results at 800 mg dosing
- Advancement to higher dose testing (1,200 mg)
- Demonstrated pan-viral activity against multiple norovirus strains
- First potential antiviral treatment for norovirus addressing significant unmet need
Negative
- Human challenge study not starting until later in 2025
- Additional testing required before efficacy can be confirmed
Insights
The Phase 1 results for CDI-988 represent a important milestone in addressing the significant unmet need for norovirus treatment. The drug demonstrated favorable safety and tolerability at doses up to 800 mg daily for 10 days, with plans to test an even higher 1,200 mg dose for 5 days. The safety profile supports advancement to efficacy studies, particularly notable given the drug's pan-viral mechanism targeting both norovirus and coronavirus proteases.
From a clinical development perspective, the planned human challenge study in norovirus-infected subjects will be pivotal in demonstrating real-world efficacy. The timing aligns well with the current surge in norovirus outbreaks, particularly in confined settings like cruise ships where 900 passengers were affected in December alone. The broad-spectrum potential of CDI-988 as both a prophylactic and treatment option could represent a significant advancement in viral outbreak management.
The drug's mechanism targeting the highly conserved 3CL protease region suggests potential durability against viral mutations, a critical factor for long-term therapeutic value. Activity against multiple norovirus strains, especially the problematic GII.4 viruses, indicates robust pan-viral coverage.
This development holds substantial market potential given the complete absence of approved antivirals or vaccines for norovirus. The timing is particularly advantageous with the current surge in outbreaks. For COCP, with a market cap of
The drug's dual potential as both a prophylactic and treatment option opens multiple market opportunities. The cruise industry alone represents a compelling initial market, with recent outbreaks highlighting the urgent need for effective interventions. The broader application potential across various viral infections, including coronaviruses, expands the total addressable market substantially.
The positive Phase 1 results and planned advancement to human challenge studies in 2025 provide clear near-term catalysts for potential value creation. The unique position as a first-in-class pan-viral protease inhibitor could command premium pricing if approved, particularly in institutional settings where outbreak prevention is critical.
- Data show favorable safety and tolerability with dosing up to 800 mg for 10 days
- Plans to initiate human challenge study in 2025 in norovirus-infected subjects
BOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces favorable safety and tolerability results at dosing up to 800 mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-988, the first pan-viral drug candidate in development as an orally administered treatment of norovirus and coronavirus infections. The Company also announces that an additional cohort with a higher dose of 1,200 mg and a shorter treatment duration of five consecutive days will be conducted to further assess CDI-988’s safety, tolerability and pharmacokinetics.
“Norovirus outbreaks are surging across the U.S. as well as on cruise ships with nearly 900 passengers sickened from gastrointestinal disease in December alone,” said Sam Lee, Ph.D., Cocrystal’s President and co-CEO. “There are currently no approved antivirals or vaccines for norovirus and the ability to curtail outbreaks is limited, making norovirus infection a significant unmet need. We are pleased to report positive Phase 1 results with these data demonstrating that CDI-988 had a favorable safety profile and was well-tolerated, supporting further clinical advancement of this potentially first effective norovirus antiviral.
“CDI-988 is our first pan-viral protease inhibitor with the potential to be used for prophylaxis and treatment for norovirus and coronavirus infections. We look forward to making a significant impact on norovirus outbreaks with this development candidate,” he added. “We expect to begin enrollment in the Phase 1 study higher-dose cohort in the current quarter and to initiate a human challenge study in norovirus-infected subjects later in 2025.”
CDI-988 is a potent, oral, broad-spectrum antiviral inhibitor of a highly conserved region in the active site of noroviruses, coronaviruses and other 3CL viral proteases. It was specifically designed and developed using Cocrystal’s proprietary structure-based drug discovery platform technology. CDI-988 has shown pan-viral activity against multiple norovirus strains, including the genogroup II, genotype 4 (GII.4) viruses that cause severe vomiting, diarrhea and stomach pain.
About Noroviruses
Human noroviruses are highly contagious, constantly evolving, extremely stable in the environment and associated with debilitating illness. Outbreaks occur most commonly in semi-closed communities such as nursing homes, hospitals, cruise ships, schools, disaster relief sites and military settings. Symptoms include vomiting and diarrhea, with or without nausea and abdominal cramps. Norovirus infection can be much more severe and prolonged in specific risk groups including infants, children, the elderly and people with immunodeficiency.
According to the Centers for Disease Control and Prevention (CDC), an estimated 685 million cases and an estimated 200,000 deaths are attributed to norovirus each year worldwide, with an estimated societal cost of approximately
Structure-Based Platform Technology
Cocrystal’s proprietary structural biology, along with its expertise in enzymology and medicinal chemistry, enable its development of novel antiviral agents. The Company’s platform provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, providing immediate insight to guide Structure Activity Relationships. This helps to identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate the development of best-in-class antiviral therapies that have fast onset of action and/or shortened treatment time, are safe, well tolerated and easy to administer, are effective against all viral subtypes that cause disease and have a high barrier to viral resistance.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Cocrystal’s plans to initiate a human challenge study in 2025 and the expansion of the current ongoing clinical trial with a higher dosage during the current quarter. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, risks relating to our ability to obtain regulatory authority for and proceed with clinical trials including the recruiting of volunteers for such studies by our clinical research organizations and vendors, the results of such studies, our collaboration partners’ technology and software performing as expected, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes, and potential development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government, and potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2023. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com
# # #
FAQ
What were the Phase 1 results for Cocrystal's CDI-988 (COCP) norovirus treatment?
When will Cocrystal Pharma (COCP) begin its norovirus human challenge study?
What is the next step in CDI-988's clinical development for COCP?
What viral strains does Cocrystal's CDI-988 (COCP) target?
How many people were affected by norovirus on cruise ships in December 2024?
